Moderna shares surged 177% in a historic one-day rally, sending moderna stock sharply higher after the biotechnology company and Merck reported encouraging results from a late-stage trial of their personalized mRNA cancer vaccine.
The dramatic jump came after the treatment showed significant benefits in helping prevent melanoma from returning and spreading, giving investors renewed confidence in Moderna’s future beyond its COVID-19 vaccine business.
Cancer Vaccine Drives Massive Rally
The Phase 3 trial tested Moderna’s personalized cancer vaccine, intismeran autogene, in combination with Merck’s Keytruda immunotherapy. The study involved more than 1,000 patients with high-risk melanoma whose tumors had been surgically removed. The companies said the combination achieved its key goals, including improving recurrence-free survival and distant metastasis-free survival compared with Keytruda alone.
The results represented a major moment for Moderna, which became one of the best-known vaccine companies during the COVID-19 pandemic. As demand for COVID vaccines declined, however, the company faced pressure to demonstrate that its mRNA technology could produce successful medicines in other areas. The melanoma results offered investors a potentially important new growth opportunity.
Moderna’s stock jumped to around $174 after the announcement, representing its largest-ever single-day gain. The move also created significant losses for investors who had bet against the company. Short sellers reportedly suffered about $5.5 billion in mark-to-market losses from the one-day rally.
A New Future Beyond COVID
The cancer vaccine works by using mRNA technology to help train a patient’s immune system to recognize mutations specific to their tumor. Researchers hope the personalized approach can help prevent cancer cells from returning after surgery and reduce the risk of the disease spreading to other parts of the body.
For Moderna, the trial success could strengthen its effort to become a broader biotechnology company rather than remaining heavily associated with COVID-19 vaccines. The company is developing mRNA medicines for a range of diseases, while additional cancer studies are also underway.
The results have also attracted attention across the biotechnology sector. Merck shares gained strongly following the announcement, while other companies working on mRNA-based cancer treatments also benefited from renewed investor enthusiasm.
Despite the dramatic stock move, the cancer vaccine still needs to progress through regulatory review before it can become an approved treatment. Moderna and Merck are expected to present more detailed trial data and engage with regulators as they work toward potential approvals.
The breakthrough gives Moderna a major opportunity to reshape its future. After years of being closely identified with COVID-19 vaccines, the company is now betting that personalized mRNA technology can play a much larger role in cancer treatment and create a new chapter for the business.
Source : nytimes.com
The 2DayBulletins Editorial Team publishes accurate, timely, and well-researched news and articles across Trending Topics , Business and Finance , Politics, Entertainment, Sports, Technology, Health, with a focus on delivering reliable information to readers.